User contributions
Jump to navigation
Jump to search
- 23:11, 22 April 2024 diff hist +6 m Multiple myeloma - historical
- 23:10, 22 April 2024 diff hist +7 m Multiple myeloma - historical →Subsequent treatment
- 23:06, 22 April 2024 diff hist +1,516 N Nogapendekin alfa inbakicept (Anktiva) Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nogapendekin-alfa NCI Drug Dictionary]: A fusion protein complex composed of..." current
- 23:00, 22 April 2024 diff hist +74 m Drug index →N
- 13:14, 22 April 2024 diff hist +14 m Breast cancer, ER-positive →Adjuvant therapy, premenopausal
- 13:13, 22 April 2024 diff hist +2,251 m Breast cancer, ER-positive →Goserelin & Tamoxifen {{#subobject:23ef1e|Regimen=1}}
- 13:13, 22 April 2024 diff hist +12 m Breast cancer, ER-positive
- 13:12, 22 April 2024 diff hist +2,256 Breast cancer, ER-positive →Adjuvant therapy, premenopausal
- 13:09, 22 April 2024 diff hist +2,763 m Breast cancer, ER-positive →Anastrozole monotherapy {{#subobject:a052f4|Regimen=1}}
- 13:05, 22 April 2024 diff hist +2 m Breast cancer, ER-positive
- 13:05, 22 April 2024 diff hist +2,760 Breast cancer, ER-positive →Letrozole monotherapy {{#subobject:55e6f9|Regimen=1}}
- 12:52, 22 April 2024 diff hist +630 m Chronic myeloid leukemia →Imatinib monotherapy {{#subobject:917a16|Regimen=1}}
- 16:46, 21 April 2024 diff hist +6 m Ewing sarcoma
- 16:42, 21 April 2024 diff hist +7 m Esophageal cancer →Subsequent treatment
- 16:40, 21 April 2024 diff hist +7 m Diffuse large B-cell lymphoma →Subsequent treatment
- 16:38, 21 April 2024 diff hist +96 m Classical Hodgkin lymphoma
- 16:34, 21 April 2024 diff hist +7 m Breast cancer →Subsequent treatment
- 16:33, 21 April 2024 diff hist +7 m Breast cancer →Subsequent treatment
- 12:52, 21 April 2024 diff hist +7 m Breast cancer, ER-positive →Preceding treatment
- 12:48, 21 April 2024 diff hist +12 m Breast cancer - historical
- 12:46, 21 April 2024 diff hist -51 m Acute promyelocytic leukemia
- 12:42, 21 April 2024 diff hist +12 m Acute myeloid leukemia - historical →DAT {{#subobject:fc4f58|Regimen=1}}
- 20:15, 20 April 2024 diff hist +2,200 m Non-small cell lung cancer →Carboplatin & Docetaxel {{#subobject:bdce59|Regimen=1}}
- 20:06, 20 April 2024 diff hist +1,560 m Breast cancer - historical →STAMP-I {{#subobject:c08ab4|Regimen=1}}
- 20:05, 20 April 2024 diff hist -1,561 m Breast cancer - historical →VAP {{#subobject:4b99b8|Regimen=1}}
- 20:04, 20 April 2024 diff hist +513 m Breast cancer - historical →CTCb, then auto HSCT {{#subobject:02f569|Regimen=1}}
- 19:55, 20 April 2024 diff hist +2,042 m Breast cancer - historical →CHUT, then auto HSCT {{#subobject:e9e363|Regimen=1}}
- 19:55, 20 April 2024 diff hist -2,042 m Breast cancer - historical →CTCb, then auto HSCT {{#subobject:02f569|Regimen=1}}
- 19:54, 20 April 2024 diff hist +2,013 m Breast cancer - historical →CHUT, then auto HSCT {{#subobject:e9e363|Regimen=1}}
- 19:53, 20 April 2024 diff hist +1,366 m Breast cancer - historical →Mitoxantrone & Vinorelbine (MV) {{#subobject:eb48ba|Regimen=1}}
- 19:50, 20 April 2024 diff hist -2,555 m Breast cancer - historical →STAMP-I {{#subobject:c08ab4|Regimen=1}}
- 19:47, 20 April 2024 diff hist +61 m Breast cancer - historical →Metastatic disease, first-line therapy
- 18:32, 20 April 2024 diff hist +118 m Acute myeloid leukemia →Upfront induction therapy, standard and older "fit" patients
- 12:56, 20 April 2024 diff hist +44 m Esophageal cancer →References
- 12:54, 20 April 2024 diff hist +68 m Esophageal cancer
- 00:40, 20 April 2024 diff hist -140 m Cutaneous squamous cell carcinoma
- 00:39, 20 April 2024 diff hist +69 m Classical Hodgkin lymphoma
- 00:37, 20 April 2024 diff hist +845 m Classical Hodgkin lymphoma
- 00:37, 20 April 2024 diff hist -7 m Autologous HSCT →References
- 00:36, 20 April 2024 diff hist +63 m Autologous HSCT →Regimen {{#subobject:81ff2e|Variant=1}}
- 00:22, 20 April 2024 diff hist +35 m Head and neck cancer
- 00:20, 20 April 2024 diff hist +186 m Colorectal cancer
- 00:17, 20 April 2024 diff hist +251 m Non-small cell lung cancer
- 00:11, 20 April 2024 diff hist +69 m Malignant solid neoplasm, ERBB2-mutated →Trastuzumab emtansine monotherapy {{#subobject:0a0a41|Regimen=1}} current
- 00:10, 20 April 2024 diff hist +67 m Malignant solid neoplasm, ERBB2-mutated →Neratinib monotherapy {{#subobject:3c1a9c|Regimen=1}}
- 00:09, 20 April 2024 diff hist +1,507 Malignant solid neoplasm, ERBB2-mutated →Trastuzumab emtansine monotherapy {{#subobject:0a0a41|Regimen=1}}
- 00:03, 20 April 2024 diff hist +453 m Trastuzumab deruxtecan (Enhertu) current
- 23:55, 19 April 2024 diff hist 0 m Urothelial carcinoma
- 23:50, 19 April 2024 diff hist +3 m Melanoma →Regimen variant #1, 2 mg/kg q3wk {{#subobject:25a9fe|Variant=1}}
- 23:49, 19 April 2024 diff hist +3 m Melanoma →Regimen variant #2, indefinite {{#subobject:722e51|Variant=1}}
- 16:37, 19 April 2024 diff hist +230 m Opioid Conversion Table current
- 16:22, 19 April 2024 diff hist +745 m B-cell acute lymphoblastic leukemia, pediatric →References
- 12:34, 19 April 2024 diff hist 0 m Mantle cell lymphoma →Lenalidomide monotherapy {{#subobject:b5de78|Regimen=1}}
- 12:32, 19 April 2024 diff hist +594 m Head and neck cancer →Methotrexate monotherapy {{#subobject:0e90b2|Regimen=1}}
- 12:30, 19 April 2024 diff hist +280 m Glioblastoma →Carmustine & RT {{#subobject:ee9fbd|Regimen=1}}
- 12:25, 19 April 2024 diff hist +293 m Head and neck cancer →Cetuximab monotherapy {{#subobject:4b973b|Regimen=1}}
- 12:24, 19 April 2024 diff hist +933 m Head and neck cancer →Docetaxel monotherapy {{#subobject:623c3f|Regimen=1}}
- 12:15, 19 April 2024 diff hist -36 m B-cell acute lymphoblastic leukemia, Ph-positive →Dasatinib, Vincristine, Prednisone {{#subobject:71a41c|Regimen=1}}
- 12:11, 19 April 2024 diff hist +3 m Acute myeloid leukemia, FLT3-positive →Regimen {{#subobject:bd7f87|Variant=1}}
- 12:11, 19 April 2024 diff hist +3 m Acute myeloid leukemia, FLT3-positive →FLAG-Ida {{#subobject:d8c75b|Regimen=1}}
- 12:10, 19 April 2024 diff hist +3 m Acute myeloid leukemia, FLT3-positive →Regimen {{#subobject:c9nqa0|Variant=1}}
- 11:17, 19 April 2024 diff hist +337 m Chronic lymphocytic leukemia →Ofatumumab monotherapy {{#subobject:75bd7e|Regimen=1}}
- 11:12, 19 April 2024 diff hist -4 m Breast cancer, triple negative
- 11:11, 19 April 2024 diff hist -1 m Breast cancer, triple negative →Paclitaxel & Pembrolizumab {{#subobject:2g8gua|Regimen=1}}
- 11:07, 19 April 2024 diff hist +29 m Breast cancer, BRCA-mutated →Regimen variant #2, 300 mg twice per day {{#subobject:3b0774|Variant=1}}
- 11:00, 19 April 2024 diff hist +8 m Colorectal cancer, MSI-H or dMMR →Regimen {{#subobject:3af038|Variant=1}}
- 11:00, 19 April 2024 diff hist +2 m Colorectal cancer, MSI-H or dMMR →Regimen {{#subobject:3af038|Variant=1}}
- 10:59, 19 April 2024 diff hist -65 m Colorectal cancer, MSI-H or dMMR →Pembrolizumab monotherapy {{#subobject:5aa59d|Regimen=1}}
- 00:36, 19 April 2024 diff hist -1 m Esophageal squamous cell carcinoma →Nivolumab monotherapy {{#subobject:10ee99|Regimen=1}}
- 00:35, 19 April 2024 diff hist -1 m Esophageal squamous cell carcinoma →Regimen {{#subobject:d1dde0|Variant=1}}
- 00:35, 19 April 2024 diff hist +29 m Esophageal squamous cell carcinoma →Camrelizumab monotherapy {{#subobject:c701c3|Regimen=1}}
- 00:29, 19 April 2024 diff hist -39 m Non-small cell lung cancer, nonsquamous →Regimen variant #2, 5/500 x 4, then maintenance pem x 2y {{#subobject:1mwjm3|Variant=1}}
- 00:19, 19 April 2024 diff hist +1,816 Ovarian cancer, HRD-positive →Paclitaxel monotherapy {{#subobject:f47paa|Regimen=1}}
- 00:17, 19 April 2024 diff hist +1,791 Ovarian cancer, HRD-positive →Paclitaxel monotherapy {{#subobject:f47paa|Regimen=1}}
- 00:16, 19 April 2024 diff hist +1,794 Ovarian cancer, HRD-positive →Olaparib monotherapy {{#subobject:f47yha|Regimen=1}}
- 00:14, 19 April 2024 diff hist +686 m Ovarian cancer, HRD-positive
- 00:14, 19 April 2024 diff hist -686 m Ovarian cancer, HRD-positive
- 00:13, 19 April 2024 diff hist +1,813 Ovarian cancer, HRD-positive →Olaparib monotherapy {{#subobject:f47yha|Regimen=1}}
- 23:47, 18 April 2024 diff hist -2 m Gastric cancer, HER2-positive →Regimen {{#subobject:577cd6|Variant=1}}
- 23:44, 18 April 2024 diff hist +3 m Peripheral T-cell lymphoma →References
- 23:44, 18 April 2024 diff hist +19 m Peripheral T-cell lymphoma →Gemcitabine monotherapy {{#subobject:7dbc1c|Regimen=1}}
- 23:43, 18 April 2024 diff hist +2 m Peripheral T-cell lymphoma - historical →References
- 23:39, 18 April 2024 diff hist +807 m Clear cell renal cell carcinoma
- 23:36, 18 April 2024 diff hist +730 m Clear cell renal cell carcinoma - null regimens →Placebo current
- 20:40, 18 April 2024 diff hist +4 m Non-small cell lung cancer, ALK-positive →Regimen {{#subobject:9cef11|Variant=1}}
- 20:39, 18 April 2024 diff hist +255 m Alectinib (Alecensa) →History of changes in FDA indication current
- 17:14, 16 April 2024 diff hist -1 m Drug shortages →Links current
- 19:37, 15 April 2024 diff hist +38 m Multiple myeloma - historical →Melphalan monotherapy, then auto HSCT, then Melphalan & TBI, then auto HSCT {{#subobject:9ac748|Regimen=1}}
- 19:31, 15 April 2024 diff hist 0 m Multiple myeloma - historical →Melphalan monotherapy, then auto HSCT, then Melphalan & Busulfan, then auto HSCT {{#subobject:71ae0c|Regimen=1}}
- 19:30, 15 April 2024 diff hist +308 m Multiple myeloma - historical →MEL200, then auto HSCT, then MEL220 & Dexamethasone, then auto HSCT {{#subobject:9f3119|Regimen=1}}
- 19:25, 15 April 2024 diff hist +330 m Multiple myeloma - historical →Melphalan monotherapy, then auto HSCT, then Melphalan & Busulfan, then auto HSCT {{#subobject:71ae0c|Regimen=1}}
- 19:20, 15 April 2024 diff hist -1 m Multiple myeloma, consolidation and maintenance →Thalidomide & Prednisolone (TP) {{#subobject:1agdc9|Regimen=1}}
- 18:42, 15 April 2024 diff hist +255 m Follicular lymphoma - historical →131Iodine-Tositumomab monotherapy {{#subobject:f69726|Regimen=1}}
- 17:48, 15 April 2024 diff hist -1 m Breast cancer - historical →CEF/CMF {{#subobject:682333|Regimen=1}}
- 17:04, 15 April 2024 diff hist +16 m CNS lymphoma →Nordic Regimen, younger patients {{#subobject:e571ce|Regimen=1}}
- 17:02, 15 April 2024 diff hist +2 m Rhabdomyosarcoma, pediatric
- 17:35, 14 April 2024 diff hist -39 m Urothelial carcinoma - null regimens →Preceding treatment current
- 17:35, 14 April 2024 diff hist -13 m Urothelial carcinoma →Preceding treatment
- 17:34, 14 April 2024 diff hist +12 m Urothelial carcinoma - null regimens →Preceding treatment
- 17:33, 14 April 2024 diff hist +9 m Testicular cancer →Regimen variant #5, 45/500/100 (modified BEP) {{#subobject:fd61db|Variant=1}}
- 17:31, 14 April 2024 diff hist +328 m Osteosarcoma - null regimens current
- 17:29, 14 April 2024 diff hist +45 m Non-small cell lung cancer, nonsquamous →Maintenance after first-line therapy
- 17:28, 14 April 2024 diff hist +33 m Non-small cell lung cancer, nonsquamous →Consolidation after definitive therapy for inoperable disease
- 17:27, 14 April 2024 diff hist -70 m Non-small cell lung cancer - historical
- 17:25, 14 April 2024 diff hist +74 m Multiple myeloma - historical
- 17:23, 14 April 2024 diff hist +140 m Multiple myeloma, consolidation and maintenance
- 17:21, 14 April 2024 diff hist +9 m Mantle cell lymphoma →Preceding treatment
- 17:20, 14 April 2024 diff hist +26 m Mantle cell lymphoma →Brexucabtagene autoleucel monotherapy {{#subobject:4z3u14|Regimen=1}}
- 17:19, 14 April 2024 diff hist +10 m Low-grade glioma →Regimen variant #3, continuous therapy {{#subobject:3871fe|Variant=1}}
- 17:19, 14 April 2024 diff hist +24 m Light-chain (AL) amyloidosis →Relapsed or refractory
- 17:16, 14 April 2024 diff hist +43 m Glioblastoma →Maintenance after first-line therapy
- 12:49, 14 April 2024 diff hist +44 m Ewing sarcoma
- 12:48, 14 April 2024 diff hist -36 m Acute promyelocytic leukemia
- 12:43, 14 April 2024 diff hist +355 m Diffuse large B-cell lymphoma
- 11:27, 14 April 2024 diff hist +69 m Small cell lung cancer - historical
- 11:09, 14 April 2024 diff hist +1,805 m Paroxysmal nocturnal hemoglobinuria →Iptacopan monotherapy {{#subobject:aa617d |Regimen=1}}
- 10:43, 14 April 2024 diff hist +58 m Paroxysmal nocturnal hemoglobinuria →References
- 10:41, 14 April 2024 diff hist +56 m Drug index →I
- 10:40, 14 April 2024 diff hist -25 m Drug index →I
- 10:40, 14 April 2024 diff hist +125 m Iptacopan (Fabhalta) current
- 10:38, 14 April 2024 diff hist +34 N Iptacopan (LNP-023) Jwarner moved page Iptacopan (LNP-023) to Iptacopan (Fabhalta): FDA approval current Tag: New redirect
- 10:38, 14 April 2024 diff hist 0 m Iptacopan (Fabhalta) Jwarner moved page Iptacopan (LNP-023) to Iptacopan (Fabhalta): FDA approval
- 10:38, 14 April 2024 diff hist +248 m Iptacopan (Fabhalta)
- 10:34, 14 April 2024 diff hist -223 m Pheochromocytoma →Sunitinib monotherapy {{#subobject:ec3261|Regimen=1}}
- 10:33, 14 April 2024 diff hist +2,063 Pheochromocytoma →All lines of therapy
- 15:29, 13 April 2024 diff hist +82 m Follicular lymphoma →Maintenance after subsequent lines of therapy
- 15:27, 13 April 2024 diff hist +55 m Follicular lymphoma →Consolidation after subsequent lines of therapy
- 15:25, 13 April 2024 diff hist +227 m Follicular lymphoma →Maintenance after first-line therapy
- 15:22, 13 April 2024 diff hist +204 m Follicular lymphoma →Consolidation after first-line therapy
- 15:17, 13 April 2024 diff hist +11 m Follicular lymphoma →Observation
- 15:17, 13 April 2024 diff hist +27 m Follicular lymphoma →Radiation therapy {{#subobject:6298df|Regimen=1}}
- 15:14, 13 April 2024 diff hist +10 m Esophageal cancer →Definitive therapy
- 15:13, 13 April 2024 diff hist +11 m Esophageal cancer →Preceding treatment
- 15:12, 13 April 2024 diff hist +1 m Diffuse large B-cell lymphoma →Lenalidomide monotherapy {{#subobject:e4284f|Regimen=1}}
- 15:11, 13 April 2024 diff hist +230 m Diffuse large B-cell lymphoma →Relapsed or refractory, salvage therapy
- 15:06, 13 April 2024 diff hist +61 m Diffuse large B-cell lymphoma
- 15:04, 13 April 2024 diff hist +65 m Diffuse large B-cell lymphoma →Maintenance after upfront therapy
- 15:03, 13 April 2024 diff hist +217 m Diffuse large B-cell lymphoma →Consolidation after upfront therapy
- 15:00, 13 April 2024 diff hist +58 m Diffuse large B-cell lymphoma - null regimens current
- 14:58, 13 April 2024 diff hist +10 m Diffuse large B-cell lymphoma - historical →Consolidation after upfront therapy
- 14:57, 13 April 2024 diff hist +12 m Colorectal cancer →Advanced or metastatic disease, third-line therapy
- 14:56, 13 April 2024 diff hist +33 m Colorectal cancer →Advanced or metastatic disease, second-line therapy
- 14:56, 13 April 2024 diff hist +25 m Colorectal cancer →Advanced or metastatic disease, first-line
- 14:54, 13 April 2024 diff hist +88 m Colorectal cancer →Maintenance after first-line therapy
- 12:54, 13 April 2024 diff hist +77 m CNS lymphoma →Relapsed or refractory, salvage therapy
- 12:54, 13 April 2024 diff hist +285 m CNS lymphoma →Consolidation after upfront therapy
- 12:51, 13 April 2024 diff hist +87 m CNS lymphoma →Upfront therapy, non-randomized or retrospective data
- 12:49, 13 April 2024 diff hist +107 m CNS lymphoma →Upfront therapy, randomized data
- 12:47, 13 April 2024 diff hist +11 m CNS lymphoma →Methotrexate monotherapy {{#subobject:e89965|Regimen=1}}
- 12:47, 13 April 2024 diff hist +20 m CNS lymphoma
- 12:46, 13 April 2024 diff hist +20 m CNS lymphoma - null regimens current
- 11:38, 13 April 2024 diff hist +30 m Pancreatic cancer →Regimen variant #2, q4wk indefinite {{#subobject:fcd708|Variant=1}}
- 11:37, 13 April 2024 diff hist +60 m Pancreatic cancer →Regimen {{#subobject:242770|Variant=1}}
- 11:35, 13 April 2024 diff hist +2,181 Pancreatic cancer →Capecitabine monotherapy {{#subobject:38b5c7|Regimen=1}}
- 00:22, 13 April 2024 diff hist +39 m Classical Hodgkin lymphoma - historical
- 00:20, 13 April 2024 diff hist +79 m Classical Hodgkin lymphoma - null regimens current
- 00:19, 13 April 2024 diff hist +1,517 m Classical Hodgkin lymphoma
- 23:54, 12 April 2024 diff hist +68 m Chronic myeloid leukemia
- 23:53, 12 April 2024 diff hist +13 m Chronic myeloid leukemia →Subsequent treatment
- 23:52, 12 April 2024 diff hist +44 m Chronic myeloid leukemia →Imatinib monotherapy {{#subobject:6cdc45|Regimen=1}}
- 23:49, 12 April 2024 diff hist +14 m Breast cancer, HER2-positive →Preceding treatment
- 23:47, 12 April 2024 diff hist +241 m Breast cancer, ER-positive
- 23:41, 12 April 2024 diff hist +25 m Bladder cancer →Induction chemoradiotherapy
- 23:40, 12 April 2024 diff hist +27 m B-cell acute lymphoblastic leukemia →Preceding treatment
- 23:38, 12 April 2024 diff hist +10 m Anaplastic glioma →Preceding treatment
- 18:31, 12 April 2024 diff hist +2,514 m Clear cell renal cell carcinoma
- 18:26, 12 April 2024 diff hist +944 m Breast cancer - null regimens →References
- 18:26, 12 April 2024 diff hist +944 m Breast cancer, BRCA-mutated →References
- 18:06, 12 April 2024 diff hist +16 m CARv3-TEAM-E T-cells current
- 18:05, 12 April 2024 diff hist +658 N CARv3-TEAM-E T-cells Created page with "==Mechanism of action== anti-EGFR CAR T-cells ==Preliminary data== ===Glioblastoma=== #'''INCIPIENT:''' Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Ni..."
- 18:03, 12 April 2024 diff hist +26 m Drug index →C
- 18:00, 12 April 2024 diff hist +34 N Category:SPEAR T-cells Created page with "Category:Immune effector cells" current
- 18:00, 12 April 2024 diff hist +26 N Category:Anti-MAGE-A4 SPEAR T-cells Created page with "Category:SPEAR T-cells" current
- 17:59, 12 April 2024 diff hist -35 m Afamitresgene Autoleucel (ADP-A2M4) current
- 17:59, 12 April 2024 diff hist +36 N Category:Liposarcoma medications (investigational) Created page with "Category:Liposarcoma medications" current
- 17:59, 12 April 2024 diff hist +1,888 N Afamitresgene Autoleucel (ADP-A2M4) Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/afamitresgene-autoleucel NCI Drug Dictionary]: A preparation of autologous h..."
- 17:54, 12 April 2024 diff hist +41 m Drug index →A
- 10:17, 12 April 2024 diff hist +81 m Breast cancer, ER-positive - null regimens current
- 10:15, 12 April 2024 diff hist +8,424 m Breast cancer - historical →CHUT, then auto HSCT {{#subobject:e9e363|Regimen=1}}
- 10:15, 12 April 2024 diff hist -8,424 m Breast cancer - historical →CAV {{#subobject:90f8d0|Regimen=1}}
- 00:18, 12 April 2024 diff hist +3,422 Non-small cell lung cancer, ALK-positive →Carboplatin & Pemetrexed {{#subobject:b94ckc|Regimen=1}}
- 00:16, 12 April 2024 diff hist +3,428 Non-small cell lung cancer, ALK-positive →Cisplatin & Pemetrexed {{#subobject:b9uc2c|Regimen=1}}
- 00:13, 12 April 2024 diff hist 0 m Non-small cell lung cancer, ALK-positive →Regimen variant #2, 750 mg/day fasting {{#subobject:47c6e4|Variant=1}}
- 00:13, 12 April 2024 diff hist +4 m Non-small cell lung cancer, ALK-positive
- 00:12, 12 April 2024 diff hist +1,691 m Non-small cell lung cancer, ALK-positive →Carboplatin & Pemetrexed {{#subobject:b94ckc|Regimen=1}}
- 17:47, 11 April 2024 diff hist +6 m Non-small cell lung cancer, ALK-positive
- 17:47, 11 April 2024 diff hist +1,691 Non-small cell lung cancer, ALK-positive →Alectinib monotherapy {{#subobject:bbc3cc|Regimen=1}}
- 15:48, 11 April 2024 diff hist +6 m Non-small cell lung cancer, ALK-positive
- 15:48, 11 April 2024 diff hist +2,021 Non-small cell lung cancer, ALK-positive →Advanced or metastatic disease, ALK inhibitor-naive
- 10:47, 11 April 2024 diff hist +1,029 m Gastric cancer →SOX {{#subobject:ecig8a|Regimen=1}}
- 10:45, 11 April 2024 diff hist +977 m Gastric cancer →SOX {{#subobject:ecig8a|Regimen=1}}
- 12:40, 10 April 2024 diff hist -4,351 m Hereditary hemorrhagic telangiectasia
- 12:40, 10 April 2024 diff hist +5,450 N Hereditary hemorrhagic telangiectasia - null regimens Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;..."
- 12:38, 10 April 2024 diff hist +265 m Hereditary hemorrhagic telangiectasia
- 12:27, 10 April 2024 diff hist +30 m Sickle cell anemia
- 12:27, 10 April 2024 diff hist +1,575 m Sickle cell anemia - null regimens →Placebo {{#subobject:9149f2|Regimen=1}} current
- 12:25, 10 April 2024 diff hist +7,736 N Sickle cell anemia - null regimens Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;..."
- 12:25, 10 April 2024 diff hist -2,018 m Sickle cell anemia
- 12:21, 10 April 2024 diff hist +246 m Sickle cell anemia
- 11:22, 10 April 2024 diff hist +215 m Smoldering multiple myeloma
- 11:21, 10 April 2024 diff hist -4,761 m Smoldering multiple myeloma
- 11:21, 10 April 2024 diff hist +5,684 N Smoldering multiple myeloma - null regimens Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;..." current
- 11:19, 10 April 2024 diff hist +255 m Smoldering multiple myeloma
- 11:48, 9 April 2024 diff hist +13 m Vincristine liposomal (Marqibo) →History of changes in FDA indication current
- 11:47, 9 April 2024 diff hist +11 m Tositumomab and I-131 (Bexxar) →History of changes in FDA indication - PARTIALLY WITHDRAWN current
- 11:46, 9 April 2024 diff hist +11 m Rucaparib (Rubraca) →History of changes in FDA indication current
- 11:45, 9 April 2024 diff hist +251 m Pembrolizumab (Keytruda) →Small cell lung cancer - WITHDRAWN current
- 11:45, 9 April 2024 diff hist +424 m Pembrolizumab (Keytruda) →Gastric or gastroesophageal junction adenocarcinoma - PARTIALLY WITHDRAWN
- 11:44, 9 April 2024 diff hist +12 m Panobinostat (Farydak) →History of changes in FDA indication current
- 11:43, 9 April 2024 diff hist +14 m Olaratumab (Lartruvo) →History of changes in FDA indication current
- 11:41, 9 April 2024 diff hist +107 m Umbralisib (Ukoniq) →History of changes in FDA indication current
- 11:38, 9 April 2024 diff hist +8 m Ibrutinib (Imbruvica) →History of changes in FDA indication - PARTIALLY WITHDRAWN current
- 11:38, 9 April 2024 diff hist +385 m Ibrutinib (Imbruvica) →History of changes in FDA indication
- 11:36, 9 April 2024 diff hist +308 m Pralsetinib (Gavreto) →History of changes in FDA indication current
- 11:34, 9 April 2024 diff hist +31 N Category:FDA withdrawn in 2024 Created page with "Category:Discontinued drugs" current
- 11:33, 9 April 2024 diff hist +225 m Copanlisib (Aliqopa) current
- 11:30, 9 April 2024 diff hist +10 m Olaparib (Lynparza) →Ovarian cancer - PARTIALLY WITHDRAWN current
- 11:30, 9 April 2024 diff hist +12 m Nivolumab (Opdivo) →Small cell lung cancer - WITHDRAWN current
- 11:29, 9 April 2024 diff hist +12 m Nivolumab (Opdivo) →Hepatocellular carcinoma - PARTIALLY WITHDRAWN
- 11:29, 9 April 2024 diff hist +13 m Melphalan flufenamide (Pepaxto) →Multiple myeloma - WITHDRAWN current
- 11:23, 9 April 2024 diff hist +21 m Idelalisib (Zydelig) →History of changes in FDA indication current
- 11:23, 9 April 2024 diff hist +12 m Gemtuzumab ozogamicin (Mylotarg) →History of changes in FDA indication current
- 11:22, 9 April 2024 diff hist +12 m Gefitinib (Iressa) →Non-small cell lung cancer - PARTIALLY WITHDRAWN current
- 11:21, 9 April 2024 diff hist -116 m Duvelisib (Copiktra) →History of changes in FDA indication current
- 11:18, 9 April 2024 diff hist +12 m Bevacizumab (Avastin) →Breast cancer - WITHDRAWN current
- 11:17, 9 April 2024 diff hist +24 m Atezolizumab (Tecentriq) →Urothelial carcinoma - WITHDRAWN current
- 11:17, 9 April 2024 diff hist +12 m Atezolizumab (Tecentriq) →Breast cancer, triple negative - WITHDRAWN
- 00:50, 9 April 2024 diff hist +27 m Soft tissue sarcoma
- 00:50, 9 April 2024 diff hist 0 m Soft tissue sarcoma - null regimens current
- 00:49, 9 April 2024 diff hist +23 m Testicular cancer →Consolidation after salvage therapy
- 00:43, 9 April 2024 diff hist +81 m Non-small cell lung cancer →Maintenance after first-line therapy
- 00:42, 9 April 2024 diff hist +277 m Non-small cell lung cancer
- 23:59, 8 April 2024 diff hist +150 m Non-small cell lung cancer - null regimens current
- 22:15, 8 April 2024 diff hist +128 m Anaplastic glioma
- 20:55, 8 April 2024 diff hist +58 m Acute myeloid leukemia →Relapsed or refractory, salvage therapy
- 20:54, 8 April 2024 diff hist +21 m Acute myeloid leukemia →Maintenance after first-line therapy
- 20:53, 8 April 2024 diff hist +405 m Acute myeloid leukemia →Consolidation after upfront therapy
- 20:49, 8 April 2024 diff hist +99 m Acute myeloid leukemia →First-line induction therapy, older or "unfit" patients
- 20:47, 8 April 2024 diff hist +48 m Acute myeloid leukemia →Subsequent induction therapy, standard and older "fit" patients
- 20:47, 8 April 2024 diff hist +375 m Acute myeloid leukemia →Upfront induction therapy, standard and older "fit" patients
- 20:40, 8 April 2024 diff hist +30 m Multiple myeloma - null regimens current
- 20:39, 8 April 2024 diff hist +79 m Follicular lymphoma - historical
- 20:36, 8 April 2024 diff hist +128 m Esophageal cancer
- 20:32, 8 April 2024 diff hist +36 m Acute myeloid leukemia, pediatric - historical
- 20:31, 8 April 2024 diff hist +44 m Acute myeloid leukemia, pediatric →Consolidation after salvage therapy current
- 20:30, 8 April 2024 diff hist +14 m Acute myeloid leukemia, pediatric →Relapsed or refractory, salvage therapy
- 20:30, 8 April 2024 diff hist +38 m Acute myeloid leukemia, pediatric →Consolidation after upfront therapy
- 20:29, 8 April 2024 diff hist +43 m Acute myeloid leukemia, pediatric →Upfront induction therapy
- 20:29, 8 April 2024 diff hist +10 m Acute myeloid leukemia, pediatric
- 20:25, 8 April 2024 diff hist +14 m Acute promyelocytic leukemia →Consolidation after salvage therapy
- 20:23, 8 April 2024 diff hist +172 m Acute promyelocytic leukemia →Upfront induction therapy
- 17:50, 8 April 2024 diff hist +14 m Acute myeloid leukemia - null regimens current
- 17:48, 8 April 2024 diff hist +32 m B-cell acute lymphoblastic leukemia, Ph-positive
- 17:46, 8 April 2024 diff hist +10 m B-cell acute lymphoblastic leukemia, pediatric, Ph-positive
- 17:45, 8 April 2024 diff hist +34 m B-cell acute lymphoblastic leukemia, pediatric - historical
- 17:45, 8 April 2024 diff hist +28 m B-cell acute lymphoblastic leukemia, pediatric
- 17:42, 8 April 2024 diff hist +116 m B-cell acute lymphoblastic leukemia
- 17:35, 8 April 2024 diff hist +89 m Breast cancer, HER2-positive →Maintenance for metastatic or unresectable disease
- 17:32, 8 April 2024 diff hist 0 m Breast cancer, HER2-positive →Metastatic or unresectable disease, first-line
- 17:31, 8 April 2024 diff hist +57 m Breast cancer, HER2-positive →Adjuvant therapy
- 17:29, 8 April 2024 diff hist +82 m Breast cancer, HER2-positive →Adjuvant therapy, sequential regimens
- 17:23, 8 April 2024 diff hist +93 m Breast cancer, HER2-positive →Neoadjuvant therapy
- 17:19, 8 April 2024 diff hist +150 m Ewing sarcoma
- 17:15, 8 April 2024 diff hist +22 m Melanoma
- 17:14, 8 April 2024 diff hist +11 m Melanoma - null regimens
- 17:13, 8 April 2024 diff hist +36 m Medulloblastoma - historical
- 15:57, 8 April 2024 diff hist +41 m Mantle cell lymphoma →Maintenance after second-line therapy
- 15:56, 8 April 2024 diff hist +8 m Mantle cell lymphoma →Consolidation after second-line therapy
- 15:55, 8 April 2024 diff hist +116 m Mantle cell lymphoma →Maintenance after first-line therapy
- 15:52, 8 April 2024 diff hist +110 m Mantle cell lymphoma →Consolidation after first-line therapy
- 15:50, 8 April 2024 diff hist +186 m Mantle cell lymphoma →First-line therapy, non-randomized or retrospective data
- 15:44, 8 April 2024 diff hist +94 m Mantle cell lymphoma →First-line therapy, randomized data
- 15:43, 8 April 2024 diff hist +11 m Mantle cell lymphoma →First-line therapy, pre-phase
- 15:41, 8 April 2024 diff hist +54 m Multiple myeloma, relapsed-refractory
- 15:39, 8 April 2024 diff hist +9 m Osteosarcoma
- 15:38, 8 April 2024 diff hist 0 m Osteosarcoma - null regimens
- 15:22, 8 April 2024 diff hist 0 m Osteosarcoma - historical
- 14:42, 8 April 2024 diff hist +57 m Rectal cancer →Adjuvant chemotherapy
- 14:40, 8 April 2024 diff hist +213 m Rectal cancer →Neoadjuvant therapy
- 14:36, 8 April 2024 diff hist +36 m Rectal cancer - null regimens current
- 14:28, 8 April 2024 diff hist +205 m Small cell lung cancer →Extensive stage, induction
- 14:24, 8 April 2024 diff hist +126 m Small cell lung cancer →Limited stage, consolidation after upfront therapy
- 14:21, 8 April 2024 diff hist +2 m Small cell lung cancer →Limited stage, definitive chemoradiotherapy
- 14:20, 8 April 2024 diff hist +34 m Small cell lung cancer →Limited stage, induction
- 14:20, 8 April 2024 diff hist +53 m Small cell lung cancer - null regimens current
- 14:15, 8 April 2024 diff hist -41 m Urothelial carcinoma
- 13:23, 8 April 2024 diff hist 0 m T-cell acute lymphoblastic leukemia
- 13:22, 8 April 2024 diff hist +24 m Ovarian cancer - historical →Maintenance after second-line therapy for platinum-sensitive disease
- 13:21, 8 April 2024 diff hist +24 m Ovarian cancer - historical
- 13:20, 8 April 2024 diff hist +11 m Malignant pleural mesothelioma - null regimens current
- 13:19, 8 April 2024 diff hist +11 m Low-grade glioma - null regimens current
- 13:19, 8 April 2024 diff hist +20 m Low-grade glioma
- 13:18, 8 April 2024 diff hist +111 m HIV-associated lymphoma
- 13:16, 8 April 2024 diff hist +4 m Colorectal cancer, RAS wild-type
- 13:14, 8 April 2024 diff hist +22 m Colorectal cancer - null regimens current
- 12:58, 8 April 2024 diff hist +105 m Classical Hodgkin lymphoma, pediatric - historical
- 12:57, 8 April 2024 diff hist +262 m Classical Hodgkin lymphoma, pediatric
- 12:53, 8 April 2024 diff hist +67 m Chronic myeloid leukemia
- 12:19, 8 April 2024 diff hist -131 m Cellular therapy conditioning regimens
- 12:17, 8 April 2024 diff hist -1 m Castleman disease
- 23:23, 7 April 2024 diff hist +17 m Chronic myelomonocytic leukemia →Decitabine monotherapy {{#subobject:c9cd47|Regimen=1}}
- 23:23, 7 April 2024 diff hist +1,102 m Myelodysplastic syndrome →Decitabine monotherapy {{#subobject:c9cd47|Regimen=1}}
- 23:21, 7 April 2024 diff hist +1,103 m Chronic myelomonocytic leukemia
- 23:15, 7 April 2024 diff hist +750 m Chronic lymphocytic leukemia →References
- 23:14, 7 April 2024 diff hist +1,523 m Chronic lymphocytic leukemia →Bendamustine & Rituximab (BR) {{#subobject:7542a2|Regimen=1}}
- 23:06, 7 April 2024 diff hist +3 m Chronic lymphocytic leukemia →Ibrutinib monotherapy {{#subobject:8c370d|Regimen=1}}
- 22:53, 7 April 2024 diff hist 0 m Multiple myeloma →ASCO/CCO
- 22:52, 7 April 2024 diff hist +259 m Carcinoma of unknown primary →ESMO
- 22:51, 7 April 2024 diff hist +225 m Head and neck cancer →ASCO
- 22:47, 7 April 2024 diff hist 0 m Penile cancer →EAU-ASCO
- 22:10, 7 April 2024 diff hist +261 m Prostate cancer →ASCO
- 22:05, 7 April 2024 diff hist +306 m Ovarian cancer →ASCO
- 22:03, 7 April 2024 diff hist +234 m Ovarian cancer, HRD-positive →ASCO
- 22:02, 7 April 2024 diff hist +196 m Hepatocellular carcinoma →ASCO
- 21:57, 7 April 2024 diff hist +270 m ASCO guidelines →Bone-modifying agents
- 21:54, 7 April 2024 diff hist +1 m Breast cancer, ER-positive →ASCO
- 21:52, 7 April 2024 diff hist +526 m Breast cancer, ER and HER2 co-expressing →ASCO/CAP
- 21:51, 7 April 2024 diff hist +542 m Breast cancer, ER-positive →ASCO
- 13:44, 7 April 2024 diff hist +1,008 m Breast cancer →ASCO/CCO
- 13:38, 7 April 2024 diff hist +2 m Breast cancer →ASCO/CCO
- 13:36, 7 April 2024 diff hist +1,336 m ASCO guidelines →Cancer cachexia
- 13:31, 7 April 2024 diff hist +6 m Breast cancer, HER2-positive →ASCO
- 13:21, 7 April 2024 diff hist +2 m Breast cancer, CNS metastases →ASCO
- 13:20, 7 April 2024 diff hist +1,184 m Breast cancer, ER and HER2 co-expressing →Guidelines
- 13:19, 7 April 2024 diff hist +1,183 m Breast cancer, HER2-positive →ASCO
- 13:14, 7 April 2024 diff hist +493 m Breast cancer, BRCA-mutated →ASCO
- 13:12, 7 April 2024 diff hist +236 m Breast cancer →ASCO/CCO
- 13:09, 7 April 2024 diff hist +321 m Breast cancer, ER-positive →ASCO
- 01:30, 7 April 2024 diff hist -180 m Classical Hodgkin lymphoma, pediatric
- 00:30, 7 April 2024 diff hist +664 m Urothelial carcinoma
- 00:26, 7 April 2024 diff hist +520 m Hepatocellular carcinoma
- 00:25, 7 April 2024 diff hist +520 m Hepatocellular carcinoma - historical
- 11:02, 5 April 2024 diff hist -663 m Non-small cell lung cancer
- 11:01, 5 April 2024 diff hist -284 m Non-small cell lung cancer →Pembrolizumab monotherapy {{#subobject:430dc7|Regimen=1}}
- 21:26, 4 April 2024 diff hist -1 m Diffuse large B-cell lymphoma →R-NIMP {{#subobject:fb6d8|Regimen=1}}
- 12:23, 3 April 2024 diff hist +4 m Ovarian cancer
- 12:21, 3 April 2024 diff hist +4 m Medulloblastoma
- 11:10, 2 April 2024 diff hist +4 m Prostate cancer →Regimen variant #1, 6 cycles {{#subobject:EJCADTdoceV|Variant=1}}
- 00:08, 1 April 2024 diff hist +399 m Pembrolizumab (Keytruda) →MSI-H or dMMR tumors (tissue-agnostic)
- 00:01, 1 April 2024 diff hist +15 m Pembrolizumab (Keytruda) →Small cell lung cancer - WITHDRAWN
- 23:41, 31 March 2024 diff hist +3,631 Cervical cancer →Cisplatin & RT {{#subobject:89c649|Regimen=1}}
- 23:27, 31 March 2024 diff hist +7 m Erdafitinib (Balversa) →History of changes in FDA indication current
- 23:26, 31 March 2024 diff hist +4 m Urothelial carcinoma →Regimen variant #2 {{#subobject:47gh17|Variant=1}}
- 23:22, 31 March 2024 diff hist +76 m Malignant solid neoplasm, NTRK-mutated →References current
- 16:31, 31 March 2024 diff hist +1,808 Chronic myeloid leukemia, pediatric →Dasatinib monotherapy {{#subobject:51eb88|Regimen=1}} current
- 16:27, 31 March 2024 diff hist +1,803 m Chronic myeloid leukemia, pediatric →Imatinib monotherapy [COG AAML0123] {{#subobject:917a16|Regimen=1}}
- 13:37, 31 March 2024 diff hist +41 m Bosutinib (Bosulif) current
- 13:35, 31 March 2024 diff hist +3,312 Pyruvate kinase deficiency
- 13:25, 31 March 2024 diff hist -1,698 m Mitapivat (Pyrukynd) →Pyruvate kinase deficiency current
- 10:08, 31 March 2024 diff hist +514 m Mitapivat (Pyrukynd) →Pyruvate kinase deficiency
- 10:03, 31 March 2024 diff hist +593 m Mitapivat (Pyrukynd) →Pyruvate kinase deficiency
- 10:01, 31 March 2024 diff hist +31 m Mitapivat (Pyrukynd) →Pyruvate kinase deficiency
- 10:01, 31 March 2024 diff hist +29 m Mitapivat (Pyrukynd) →Pyruvate kinase deficiency
- 09:58, 31 March 2024 diff hist +32 m Mitapivat (Pyrukynd) →History of changes in FDA indication
- 01:19, 31 March 2024 diff hist 0 m Myelofibrosis →Lenalidomide monotherapy {{#subobject:1 |Regimen=1}}
- 00:24, 31 March 2024 diff hist 0 m Osteosarcoma - historical →MAPifn [COG AOST0331]
- 00:15, 31 March 2024 diff hist +282 m Esophageal squamous cell carcinoma →Fluorouracil, Mitomycin, RT {{#subobject:52e7mi|Regimen=1}}
- 00:10, 31 March 2024 diff hist +500 m Colorectal cancer →Intrahepatic floxuridine & IV 5-FU {{#subobject:8fjn3c|Regimen=1}}
- 22:07, 30 March 2024 diff hist +1,206 m Mantle cell lymphoma →Lenalidomide & Rituximab (R2) {{#subobject:3d8123|Regimen=1}}
- 21:43, 30 March 2024 diff hist +1,108 m B-cell acute lymphoblastic leukemia →Cyclophosphamide & TBI, then allo HSCT {{#subobject:a9e6e8|Regimen=1}}
- 20:11, 30 March 2024 diff hist +984 m Allogeneic HSCT →Busulfan & Cyclophosphamide {{#subobject:83e07a|Regimen=1}}
- 20:11, 30 March 2024 diff hist +1,124 m Myelodysplastic syndrome →Busulfan & Cyclophosphamide, then allo HSCT {{#subobject:83e07a|Regimen=1}}
- 20:09, 30 March 2024 diff hist +1,123 m Acute myeloid leukemia →Busulfan & Cyclophosphamide, then allo HSCT {{#subobject:83e07a|Regimen=1}}
- 20:07, 30 March 2024 diff hist +78 m Acute myeloid leukemia →References
- 20:05, 30 March 2024 diff hist +157 m Allogeneic HSCT →Fludarabine & TBI for haploidentical transplant
- 18:06, 30 March 2024 diff hist +776 m Myelodysplastic syndrome →References
- 18:05, 30 March 2024 diff hist +776 m Acute myeloid leukemia →References
- 18:01, 30 March 2024 diff hist +1,818 m Acute myeloid leukemia →Busulfan & Fludarabine, then allo HSCT {{#subobject:3fe0f0|Regimen=1}}
- 17:58, 30 March 2024 diff hist +2,160 Myelodysplastic syndrome →Busulfan & Cyclophosphamide, then allo HSCT {{#subobject:83e07a|Regimen=1}}
- 17:46, 30 March 2024 diff hist +31 m Myelodysplastic syndrome →Prognosis
- 17:45, 30 March 2024 diff hist +441 m Blastic plasmacytoid dendritic cell neoplasm
- 17:45, 30 March 2024 diff hist -207 m Acute myeloid leukemia →NCCN
- 17:44, 30 March 2024 diff hist +31 m Acute promyelocytic leukemia →References
- 17:43, 30 March 2024 diff hist -13 m Category:Myeloproliferative neoplasms
- 17:43, 30 March 2024 diff hist +43 N Category:Myeloid neoplasms Created page with "Category:Malignant hematologic neoplasm" current
- 17:42, 30 March 2024 diff hist +31 m Acute myeloid leukemia →Additional information
- 17:04, 30 March 2024 diff hist +1,883 m B-cell acute lymphoblastic leukemia, pediatric →Etoposide & TBI, then allo HSCT {{#subobject:b389e1|Regimen=1}}
- 01:40, 30 March 2024 diff hist +1 m Bicalutamide (Casodex) →History of changes in EMA indication current
- 01:39, 30 March 2024 diff hist +1 m BCG vaccine →History of changes in EMA indication current
- 00:34, 30 March 2024 diff hist -1 m High-grade glioma, pediatric →Temozolomide & RT {{#subobject:5fe805|Regimen=1}}
- 00:28, 30 March 2024 diff hist -1 m Anaplastic glioma →RT, then Temozolomide {{#subobject:48949a|Regimen=1}}
- 11:13, 29 March 2024 diff hist +65 m Osteosarcoma →IE {{#subobject:29f233|Regimen=1}}
- 11:07, 29 March 2024 diff hist -12 m Cervical cancer →Hydroxyurea & RT {{#subobject:b93f37|Regimen=1}}
- 11:03, 29 March 2024 diff hist +66 m Follicular lymphoma →Regimen variant #2, 3 cycles with prednisone 100 mg/m2 {{#subobject:aae4db|Variant=1}}
- 11:02, 29 March 2024 diff hist +66 m Follicular lymphoma →Regimen variant #3 {{#subobject:2a6690|Variant=1}}
- 11:02, 29 March 2024 diff hist +72 m Follicular lymphoma →Regimen variant #2 {{#subobject:d69b11|Variant=1}}
- 11:01, 29 March 2024 diff hist -26 m Pancreatic cancer →Gemcitabine & RT {{#subobject:a6e6fc|Regimen=1}}
- 10:54, 29 March 2024 diff hist -32 m Rectal cancer →Regimen variant #3, CI 5-FU, then CI 5-FU & RT, then CI 5-FU {{#subobject:da8c0d|Variant=1}}
- 10:47, 29 March 2024 diff hist +11 m Multiple myeloma - historical →DEX-IFN {{#subobject:144646|Regimen=1}}
- 01:24, 29 March 2024 diff hist +765 m Allogeneic HSCT
- 01:11, 29 March 2024 diff hist +115 m Mantle cell lymphoma →Regimen variant #2, alternating {{#subobject:baugja|Variant=1}}
- 16:00, 28 March 2024 diff hist +312 m Waldenström macroglobulinemia →BDR {{#subobject:2529c7|Regimen=1}}
- 15:36, 28 March 2024 diff hist -1 m Waldenström macroglobulinemia
- 12:37, 28 March 2024 diff hist +93 m Multiple myeloma, relapsed-refractory →Daratumumab monotherapy {{#subobject:d45aea|Regimen=1}}
- 12:33, 28 March 2024 diff hist +258 m Light-chain (AL) amyloidosis →Daratumumab monotherapy {{#subobject:866e6e|Regimen=1}}
- 11:04, 28 March 2024 diff hist -7 m Breast cancer, ER and HER2 co-expressing →Endocrine therapy
- 19:58, 27 March 2024 diff hist -14 m Hepatocellular carcinoma →References
- 19:56, 27 March 2024 diff hist +24 m Multiple myeloma, induction current
- 11:29, 27 March 2024 diff hist -1 m Peripheral T-cell lymphoma →Supportive therapy
- 11:23, 26 March 2024 diff hist +2,061 Esophageal squamous cell carcinoma →Cisplatin & Fluorouracil (CF) & Sintilimab {{#subobject:717obb|Regimen=1}}
- 11:10, 26 March 2024 diff hist +1,879 m Esophageal squamous cell carcinoma →Cisplatin & Fluorouracil (CF) {{#subobject:4d9936|Regimen=1}}
- 01:35, 26 March 2024 diff hist +5 m Acute promyelocytic leukemia →Targeted therapy
- 00:34, 26 March 2024 diff hist +1,484 m Breast cancer - historical →Melphalan monotherapy {{#subobject:b913c5|Regimen=1}}
- 00:31, 26 March 2024 diff hist -19 m Breast cancer →Metastatic disease, subsequent lines of chemotherapy
- 00:26, 26 March 2024 diff hist +1,413 m Breast cancer - historical →Melphalan monotherapy {{#subobject:b062c5|Regimen=1}}
- 00:22, 26 March 2024 diff hist -395 m Breast cancer - historical →CFP {{#subobject:b514cd|Regimen=1}}
- 00:20, 26 March 2024 diff hist +1,500 m Breast cancer - historical →Melphalan monotherapy {{#subobject:b062c5|Regimen=1}}
- 01:12, 25 March 2024 diff hist +213 m Glioblastoma →Cyclophosphamide monotherapy {{#subobject:1724a|Regimen=1}}
- 01:07, 25 March 2024 diff hist +43 m Gestational trophoblastic neoplasia →Low-risk disease, all lines of therapy
- 23:39, 24 March 2024 diff hist -192 m Breast cancer, ER and HER2 co-expressing
- 20:00, 24 March 2024 diff hist -29 m Diffuse large B-cell lymphoma
- 19:50, 24 March 2024 diff hist +12 m Melanoma, BRAF-mutated
- 18:08, 24 March 2024 diff hist +155 m Colorectal cancer, RAS wild-type →Subsequent treatment
- 18:06, 24 March 2024 diff hist +22 m Colorectal cancer, RAS wild-type
- 18:03, 24 March 2024 diff hist +619 m ASCO guidelines →Infectious diseases
- 17:59, 24 March 2024 diff hist +125 m Classical Hodgkin lymphoma - historical
- 17:48, 24 March 2024 diff hist +855 m Multiple myeloma, consolidation and maintenance
- 17:06, 24 March 2024 diff hist -3 m Transformed lymphoma
- 17:04, 24 March 2024 diff hist -2 m Thymoma
- 17:03, 24 March 2024 diff hist +38 m Stem cell mobilization regimens
- 17:00, 24 March 2024 diff hist +24 m Small cell lung cancer
- 16:56, 24 March 2024 diff hist -13 m Stem cell mobilization regimens
- 12:03, 24 March 2024 diff hist +1 m Urothelial carcinoma →Regimen variant #2, AUC 4.5/1000, indefinite {{#subobject:5f0in7|Variant=1}}
- 12:02, 24 March 2024 diff hist -51 m Urothelial carcinoma →Chemotherapy
- 11:42, 24 March 2024 diff hist +2 m Non-small cell lung cancer →References
- 11:42, 24 March 2024 diff hist +2,311 m Non-small cell lung cancer →Carboplatin & Paclitaxel (CP) {{#subobject:81d5a7|Regimen=1}}
- 11:39, 24 March 2024 diff hist +159 m Non-small cell lung cancer →Carboplatin & Paclitaxel (CP) & RT {{#subobject:899399|Regimen=1}}
- 11:37, 24 March 2024 diff hist +2,765 m Non-small cell lung cancer - historical →MVP & RT {{#subobject:10d15d|Regimen=1}}
- 11:30, 24 March 2024 diff hist +114 m Non-small cell lung cancer →Carboplatin & Paclitaxel (CP) & RT {{#subobject:899399|Regimen=1}}
- 11:24, 24 March 2024 diff hist +1,644 Neuroendocrine tumor →Everolimus monotherapy {{#subobject:99989f|Regimen=1}}
- 11:23, 24 March 2024 diff hist +54 m Neuroendocrine tumor →Fluorouracil & Streptozocin {{#subobject:bd8397|Regimen=1}}
- 11:21, 24 March 2024 diff hist -4 m Neuroendocrine tumor →Fluorouracil & Streptozocin {{#subobject:bd8397|Regimen=1}}
- 02:30, 24 March 2024 diff hist +4 m Kaposi sarcoma →Pegylated liposomal doxorubicin monotherapy {{#subobject:a880c2|Regimen=1}}
- 02:29, 24 March 2024 diff hist +1,538 Kaposi sarcoma →Bevacizumab monotherapy {{#subobject:25316e|Regimen=1}}
- 02:21, 24 March 2024 diff hist -38 m Non-small cell lung cancer
- 02:21, 24 March 2024 diff hist -18 m Malignant pleural mesothelioma
- 02:17, 24 March 2024 diff hist +150 m Breast cancer →Regimen variant #2 {{#subobject:bf8gub|Variant=1}}
- 02:10, 24 March 2024 diff hist +1,849 Breast cancer, ER-positive →Neoadjuvant endocrine therapy, postmenopausal
- 00:24, 24 March 2024 diff hist -13 m Non-small cell lung cancer
- 00:23, 24 March 2024 diff hist -13 m Head and neck cancer
- 00:23, 24 March 2024 diff hist -28 m Non-small cell lung cancer - null regimens →Observation
- 00:22, 24 March 2024 diff hist -28 m Non-small cell lung cancer - null regimens →Observation
- 00:22, 24 March 2024 diff hist -12 m Non-small cell lung cancer, nonsquamous →Tegafur & uracil monotherapy {{#subobject:ac88ea|Regimen=1}}
- 13:29, 23 March 2024 diff hist +1 m Medulloblastoma - historical →VCP [CCG-921] {{#subobject:3dy31n|Regimen=1}}
- 13:27, 23 March 2024 diff hist -11 m High-grade glioma, pediatric →Adjuvant therapy
- 13:13, 23 March 2024 diff hist 0 m Diffuse large B-cell lymphoma - historical →MINE {{#subobject:aff118|Regimen=1}}
- 13:12, 23 March 2024 diff hist -28 m Diffuse large B-cell lymphoma - historical →Relapsed or refractory, salvage therapy
- 12:42, 23 March 2024 diff hist +703 m B-cell acute lymphoblastic leukemia, pediatric, Ph-positive →Daunorubicin, Pegaspargase, Vincristine, Prednisone, Imatinib {{#subobject:d3yhc7|Regimen=1}}
- 12:37, 23 March 2024 diff hist +703 m B-cell acute lymphoblastic leukemia, pediatric, Ph-positive →Daunorubicin, Pegaspargase, Vincristine, Prednisone, Dasatinib {{#subobject:d3ob07|Regimen=1}}
- 12:25, 23 March 2024 diff hist +2,810 m B-cell acute lymphoblastic leukemia →Relapsed or refractory
- 12:25, 23 March 2024 diff hist -2,834 m B-cell acute lymphoblastic leukemia →Cytarabine & Mitoxantrone (MC) {{#subobject:6237f0|Regimen=1}}
- 12:25, 23 March 2024 diff hist -30 m B-cell acute lymphoblastic leukemia →Inotuzumab ozogamicin monotherapy {{#subobject:d90806|Regimen=1}}
- 12:19, 23 March 2024 diff hist +8 m Acute myeloid leukemia, NPM1-mutated →Cytarabine & Etoposide {{#subobject:e8gacb|Regimen=1}}
- 12:13, 23 March 2024 diff hist -27 m Diffuse large B-cell lymphoma
- 11:28, 23 March 2024 diff hist +34 m Mantle cell lymphoma →maxi-R-CHOP/R-HiDAC {{#subobject:360f9d|Regimen=1}}
- 11:17, 23 March 2024 diff hist 0 m Small cell lung cancer
- 11:16, 23 March 2024 diff hist +5,168 m Small cell lung cancer - historical →CDE {{#subobject:344f89|Regimen=1}}
- 11:11, 23 March 2024 diff hist -5,212 m Small cell lung cancer - historical →ACE {{#subobject:9fbf31|Regimen=1}}
- 11:02, 23 March 2024 diff hist +12 m Mantle cell lymphoma
- 11:01, 23 March 2024 diff hist +2 m Mantle cell lymphoma →R-MACLO/R-IVAM {{#subobject:51391f|Regimen=1}}
- 11:01, 23 March 2024 diff hist +8,730 m Mantle cell lymphoma →R-DHAC {{#subobject:ed2a61|Regimen=1}}
- 10:59, 23 March 2024 diff hist -8,411 m Mantle cell lymphoma →R-MACLO/R-IVAM {{#subobject:51391f|Regimen=1}}
- 10:52, 23 March 2024 diff hist +3 m Non-small cell lung cancer →Subsequent treatment
- 10:47, 23 March 2024 diff hist +91 m Non-small cell lung cancer - historical →VIP (Vinblastine) {{#subobject:e6f7b9|Regimen=1}}
- 10:43, 23 March 2024 diff hist +21 m Endometrial cancer
- 10:42, 23 March 2024 diff hist +1,590 m Endometrial cancer →Cisplatin & Paclitaxel {{#subobject:89fd88|Regimen=1}}
- 10:40, 23 March 2024 diff hist -1,393 m Endometrial cancer →CIM {{#subobject:ac4ecc|Regimen=1}}
- 10:39, 23 March 2024 diff hist +42 m Endometrial cancer →Adjuvant therapy
- 02:13, 23 March 2024 diff hist +1 m Multiple myeloma, consolidation and maintenance →Preceding treatment
- 02:12, 23 March 2024 diff hist +236 m Multiple myeloma - historical
- 02:09, 23 March 2024 diff hist +12 m Multiple myeloma, induction →Synopsis
- 02:02, 23 March 2024 diff hist +136 m Thymoma
- 01:57, 23 March 2024 diff hist +2,443 m Non-small cell lung cancer - historical →Cisplatin monotherapy {{#subobject:a0eb49|Regimen=1}}
- 01:56, 23 March 2024 diff hist -2,348 m Non-small cell lung cancer - historical →CAP (Platinol) {{#subobject:379e5f|Regimen=1}}
- 01:56, 23 March 2024 diff hist -52 m Ovarian cancer
- 01:55, 23 March 2024 diff hist +135 m Ovarian cancer - historical
- 01:52, 23 March 2024 diff hist -2,238 m Urothelial carcinoma →Locally advanced or metastatic disease, first-line, platinum-eligible
- 01:51, 23 March 2024 diff hist +2,272 m Urothelial carcinoma - historical →Cisplatin monotherapy {{#subobject:1af7a9|Regimen=1}}
- 01:07, 23 March 2024 diff hist +31 m Non-small cell lung cancer
- 01:07, 23 March 2024 diff hist +2,271 m Non-small cell lung cancer →Carboplatin & Gemcitabine (GCb) {{#subobject:8669e|Regimen=1}}
- 01:06, 23 March 2024 diff hist -2,243 m Non-small cell lung cancer →PCG (Carboplatin) {{#subobject:45t1c7|Regimen=1}}
- 00:58, 23 March 2024 diff hist +23 m Acute myeloid leukemia, pediatric
- 00:51, 23 March 2024 diff hist -64 m Classical Hodgkin lymphoma →Consolidation after salvage therapy
- 00:49, 23 March 2024 diff hist -50 m Allogeneic HSCT →Reduced-intensity conditioning (RIC), all lines of therapy
- 00:39, 23 March 2024 diff hist +28 m Classical Hodgkin lymphoma
- 00:37, 23 March 2024 diff hist +24 m Classical Hodgkin lymphoma
- 00:28, 23 March 2024 diff hist +123 m Acute myeloid leukemia
- 00:05, 23 March 2024 diff hist +65 m Mantle cell lymphoma - historical
- 00:03, 23 March 2024 diff hist +15 m Light-chain (AL) amyloidosis - null regimens →Subsequent treatment current
- 00:00, 23 March 2024 diff hist +83 m Light-chain (AL) amyloidosis
- 23:55, 22 March 2024 diff hist +96 m Colorectal cancer, RAS wild-type
- 20:27, 22 March 2024 diff hist +1,613 B-cell acute lymphoblastic leukemia, Ph-positive →Upfront induction therapy
- 20:20, 22 March 2024 diff hist +256 m Ponatinib (Iclusig) current
- 18:29, 22 March 2024 diff hist +307 m Mirvetuximab soravtansine (Elahere) current
- 18:29, 22 March 2024 diff hist +4 m Ovarian cancer →Regimen {{#subobject:1ugjzgu|Variant=1}}
- 18:20, 22 March 2024 diff hist -16 m Enzalutamide (Xtandi) →History of changes in FDA indication current
- 17:05, 22 March 2024 diff hist +208 m Adrenocortical carcinoma
- 17:03, 22 March 2024 diff hist -12 m Acute myeloid leukemia
- 16:59, 22 March 2024 diff hist -1 m Acquired thrombotic thrombocytopenic purpura
- 16:27, 22 March 2024 diff hist +45 m Diffuse large B-cell lymphoma →R-DHAOx {{#subobject:0d0c67|Regimen=1}}